Serum markers thrombophilia in pregnant women with Systemic Lupus Erythematosus

• Autor(a) principal: Oliveira,Vanessa Marcon de
• Data de Publicação: 2017
• Outros Autores: Figueiró-Filho,Ernesto Antonio, Ferreira,Cristiane Munaretto, Pereira,Erica Freire de Vasconcelos
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Revista Brasileira de Saúde Materno Infantil (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1519-38292017000400833
• topic: Systemic lupus erythematosus; Thrombophilia; Antiphospholipid syndrome; Pregnancy complications; hematologic

Abstract Objectives: to determine the frequency of serum markers for hereditary and acquired thrombophilia and their association with pregnancy in women with Systemic Lupus Erythematosus (SLE). Methods: a case-control study was conducted among 25 pregnant women with SLE (study group) and 32 pregnant women without known disease and with at least one previous pregnancy (control group). The presence of antiphospholipid antibodies and hereditary thrombophilia were examined in both groups. We used the y2 Test with Yates correction or Fisher's Exact Test to verify the associations and calculate the relative risk. Results: thrombophilia was present in 72.0% of pregnant women with SLE and in 6.0% of patients in the control group. A significant association was found between the presence of SLE and serum markers for hereditary thrombophilia / antiphospholipid antibodies (p<0.05). The relative risks for antiphospholipid antibodies were 13.20 (ICR95%= 1.81 - 96.46) in pregnant women with SLE, 7.26 (CI95%= 1.77 - 29.86) for the presence of serum markers of hereditary thrombophilia and 7.92 (CI95%= 2.62 - 3.94) for the presence of hereditary thrombophilia and/or antiphospholipid antibodies. Conclusions: the identification of markers for hereditary and/or acquired thrombophilia in pregnant women with lupus may be clinically useful to determine which patients have a higher risk of obstetric complications.